Neumora Therapeutics (NMRA) Competitors $1.65 +0.06 (+3.77%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.64 -0.01 (-0.61%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. EVO, EWTX, ANIP, NTLA, ETNB, VERA, BHVN, COGT, TVTX, and HROWShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Evotec (EVO), Edgewise Therapeutics (EWTX), ANI Pharmaceuticals (ANIP), Intellia Therapeutics (NTLA), 89BIO (ETNB), Vera Therapeutics (VERA), Biohaven (BHVN), Cogent Biosciences (COGT), Travere Therapeutics (TVTX), and Harrow (HROW). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Evotec Edgewise Therapeutics ANI Pharmaceuticals Intellia Therapeutics 89BIO Vera Therapeutics Biohaven Cogent Biosciences Travere Therapeutics Harrow Evotec (NASDAQ:EVO) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Which has better earnings and valuation, EVO or NMRA? Evotec has higher revenue and earnings than Neumora Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$862.40M1.59-$212.18MN/AN/ANeumora TherapeuticsN/AN/A-$243.79M-$1.57-1.05 Does the media favor EVO or NMRA? In the previous week, Neumora Therapeutics had 5 more articles in the media than Evotec. MarketBeat recorded 8 mentions for Neumora Therapeutics and 3 mentions for Evotec. Neumora Therapeutics' average media sentiment score of 0.46 beat Evotec's score of 0.46 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neumora Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is EVO or NMRA more profitable? Neumora Therapeutics has a net margin of 0.00% compared to Evotec's net margin of -26.34%. Evotec's return on equity of -21.51% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Evotec-26.34% -21.51% -10.54% Neumora Therapeutics N/A -90.44%-81.65% Do analysts rate EVO or NMRA? Evotec currently has a consensus price target of $5.90, indicating a potential upside of 52.85%. Neumora Therapeutics has a consensus price target of $7.14, indicating a potential upside of 332.90%. Given Neumora Therapeutics' higher probable upside, analysts plainly believe Neumora Therapeutics is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 Do institutionals & insiders have more ownership in EVO or NMRA? 5.8% of Evotec shares are owned by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 26.8% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, EVO or NMRA? Evotec has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500. SummaryNeumora Therapeutics beats Evotec on 8 of the 13 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$257.18M$2.98B$5.48B$9.56BDividend YieldN/A2.46%3.99%4.17%P/E Ratio-1.0517.9729.9325.14Price / SalesN/A179.55375.2276.13Price / CashN/A41.8335.9458.58Price / Book0.937.238.105.59Net Income-$243.79M-$54.43M$3.26B$265.48M7 Day Performance5.77%0.22%0.68%1.22%1 Month Performance82.99%5.59%2.45%0.39%1 Year Performance-85.32%9.98%27.72%23.47% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.9838 of 5 stars$1.65+3.8%$7.14+332.9%-86.0%$257.18MN/A-1.05108News CoverageAnalyst RevisionGap UpEVOEvotec1.9764 of 5 stars$4.26flat$5.93+39.3%+26.1%$1.51B$862.40M0.004,827Upcoming EarningsGap UpEWTXEdgewise Therapeutics2.1912 of 5 stars$14.26+1.0%$40.00+180.5%-18.5%$1.49BN/A-9.2060News CoverageEarnings ReportUpcoming EarningsGap UpANIPANI Pharmaceuticals3.7739 of 5 stars$66.50-1.5%$78.88+18.6%+21.0%$1.46B$614.38M-52.36600News CoverageNTLAIntellia Therapeutics4.2328 of 5 stars$13.11-3.6%$33.37+154.5%-46.2%$1.41B$57.88M-2.51600News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastETNB89BIO1.558 of 5 stars$9.53-0.6%$26.43+177.3%+17.0%$1.40BN/A0.0040News CoverageEarnings ReportVERAVera Therapeutics3.1479 of 5 stars$20.87-4.3%$65.00+211.5%-44.7%$1.39BN/A0.0040News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionBHVNBiohaven2.364 of 5 stars$13.10-3.0%$58.46+346.3%-55.8%$1.38BN/A-1.40239Trending NewsUpcoming EarningsCOGTCogent Biosciences3.234 of 5 stars$12.09+0.2%$18.70+54.7%+25.8%$1.37BN/A-6.5780News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionTVTXTravere Therapeutics2.0362 of 5 stars$15.40+0.5%$32.14+108.7%+100.8%$1.36B$233.18M0.00460News CoverageEarnings ReportAnalyst ForecastHROWHarrow2.3192 of 5 stars$34.86-3.7%$63.83+83.1%+51.1%$1.33B$199.61M0.00180Upcoming Earnings Related Companies and Tools Related Companies Evotec Competitors Edgewise Therapeutics Competitors ANI Pharmaceuticals Competitors Intellia Therapeutics Competitors 89BIO Competitors Vera Therapeutics Competitors Biohaven Competitors Cogent Biosciences Competitors Travere Therapeutics Competitors Harrow Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMRA Stock Alerts